Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab.

ABSTRACT:

Background

With no approved long-term prophylaxis (LTP) for the prevention of hereditary angioedema (HAE) attacks in Hong Kong, patients rely on compassionate use programs and drug trials. Moreover, studies regarding the use and efficacy of LTP in Asia are lacking.

Objectives

Our aim was to assess 2 LTP medications for HAE in Hong Kong: lanadelumab and garadacimab.

Methods

A prospective study was performed. Adult patients with a diagnosis of type I or type II HAE with 1 or more expert-confirmed attacks per month were consecutively recruited. The patients had been receiving treatment for at least 6 months. Clinical data were obtained, and questionnaires were administered before treatment periodically for at least 6 months following initiation of LTP.

Results

Alm

SUBMITTER: Wong JCY 

PROVIDER: S-EPMC10679768 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature